Abstract 【Objective】To investigate the effect of different doses of mifepristone on sex hormone levels in patients with Uterine fibroid and anemia.【Methods】From March 2019 to March 2021,90 patients with Uterine fibroid and anemia in the Pucheng County Hospital were selected and divided into observation group and control group according to random number table,with 45 cases in each group. The control group received high-dose mifepristone (20 mg/dose) treatment before surgery,while the observation group received low-dose mifepristone (10 mg/dose) treatment before surgery. The operation time,intraoperative blood loss,hospital stay,hemoglobin content 24 hours after operation,adverse reactions after medication,levels of sex hormones [luteinizing hormone (LH),progesterone (P),Follicle-stimulating hormone (FSH),estradiol (E2)],diameter of Uterine fibroid,uterine volume,and quality of life scale (QOL) scores were compared between the two groups.【Results】There was no statistically significant difference (P>0.05) between the two groups in terms of surgical time,intraoperative bleeding volume,length of hospital stay,and postoperative 24 hour hemoglobin levels; The levels of LH,P,FSH,and E2 in the two groups of patients after treatment were lower than those in the same group before treatment,and the difference was statistically significant (P<0.05); After treatment,the diameter of fibroids and uterine volume of the two groups of patients were smaller than that before treatment,and the QOL scores was higher than that before treatment,with a statistically significant difference (P<0.05); The incidence of adverse reactions after medication in the observation group (15.56%) was significantly lower than that in the control group (35.56%),with a statistically significant difference (P<0.05).【Conclusion】Preoperative use of low-dose mifepristone in patients with Uterine fibroid and anemia can effectively reduce the level of sex hormones,reduce the volume of leiomyoma,and has high safety.
DONG Lijun,WANG Wei. Effects of Different Doses of Mifepristone on Sex Hormone Levels in Patients with Uterine Fibroid and Anemia[J]. JOURNAL OF CLINICAL RESEARCH, 2023, 40(9): 1371-1374.
2023, Vol. 40 
